COPD

Results connecting breathlessness catastrophizing with reduced quality of life also have implications for populations with asthma or COPD.

Nicola Hanania, MD, MS, director of the Airways Clinical Research Center at Baylor College of Medicine, explains the latest research on COPD treatments and outlines how they all measure.

Previously approved in 2015, Stiolto Respimat Inhalation Spray is now indicated for the treatment of COPD including chronic bronchitis and emphysema.

Data from a subgroup analysis of the IMPACT study, which compared inhale triple therapy FF/UMEC/VI to dual therapy FF/VI and UMEC/VI for the treatment of COPD, has been released.

FEF25-75 may be used as a parameter for early detection of beginning small airway obstruction in smokers with normal FEV1/FVC.

A twice-daily 50 mcg dose of the nebulized LAMA therapy also had better results for patients with poor FEV1 compared to tiotropium.

Clinical research has begun to distinguish biomarkers for both conditions, research has established their similarities, and therapies are becoming pathway-based. Should asthma-COPD diagnoses be necessary?

A COPD care bundle delivered by a multidisciplinary health care team can reduce hospital readmission rates for acute exacerbations of COPD (AECOPD).

Antonion R. Anzueto, MD, covers the latest research regarding biomarkers in COPD, outlining possible avenues of investigation and addressing regional causes of the disease.

A retrospective review of rural region's hospitals found that even the discharge time of day could be associated with a greater chance of readmission.